Oculis (NASDAQ:OCS) Releases Earnings Results, Misses Estimates By $0.28 EPS

Oculis (NASDAQ:OCS) issued its earnings results on Tuesday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28), Zacks reports. Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%.

Oculis Stock Performance

NASDAQ:OCS traded down $0.10 during mid-day trading on Thursday, reaching $18.74. 20,754 shares of the company’s stock were exchanged, compared to its average volume of 84,855. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The firm has a market capitalization of $759.00 million, a PE ratio of -9.71 and a beta of 0.02. Oculis has a one year low of $10.55 and a one year high of $23.08. The business’s fifty day simple moving average is $20.86 and its two-hundred day simple moving average is $16.88.

Analyst Upgrades and Downgrades

OCS has been the topic of several research analyst reports. HC Wainwright dropped their price objective on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday. Robert W. Baird increased their price target on Oculis from $37.00 to $41.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $28.00 price target on shares of Oculis in a report on Thursday.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.